A Prospective Multicenter Phase 2 Study of FCR/BR Alternating With Ibrutinib in Treatment-naive Patients With CLL (BDHCLL001)

  • STATUS
    Recruiting
  • End date
    Dec 30, 2027
  • participants needed
    50
  • sponsor
    Institute of Hematology & Blood Diseases Hospital
Updated on 9 February 2022
lymphoid leukemia
fludarabine
anemia
cyclophosphamide
chronic lymphocytic leukemia
rituximab
fatigue
thrombocytopenia
ibrutinib
bendamustine
chlorambucil
lymphadenopathy
lymphocytosis
constitutional symptoms

Summary

This is a prospective multicenter phase 2 study designed with the purpose to evaluate the response rate and safety of treatment with FCR/BR alternating with ibrutinib in treatment-naive patients with chronic lymphocytic leukemia.

Details
Condition Chronic Lymphocytic Leukemia
Treatment FCR and Ibrutinib, BR and Ibrutinib, Ibrutinib and Thalidomide
Clinical Study IdentifierNCT03980002
SponsorInstitute of Hematology & Blood Diseases Hospital
Last Modified on9 February 2022

Eligibility

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note